1. Clinical Overview of Dihexa

Molecule: Dihexa (N-Hexanoic-Tyr-Ile-NH2) is a small-molecule neurotrophic peptide derivative developed at Washington State University to enhance HGF (Hepatocyte Growth Factor) signaling through the c-Met receptor.

Key Properties

Extremely high blood–brain barrier penetration
Potent synaptogenic effects (7× NGF activity in vitro)
Long biological half-life
Supports learning, memory formation, and neuroplasticity
Non-stimulant cognitive enhancement
Neuron-protective and anti-inflammatory effects

Primary Roles

Enhanced synaptic density
Memory formation & consolidation
Cognitive acceleration
Neuroprotection
Recovery from injury or neuroinflammation

2. Mechanisms of Action

2.1 HGF/c-Met Receptor Modulation

Dihexa acts as a potent positive allosteric modulator of the HGF/c-Met pathway. This leads to:

Increased neuronal survival
Enhanced neurite outgrowth
Synaptic formation and stabilization
Improved long-term potentiation (LTP)

Clinical benefit: Rapid and sustained improvements in cognitive function and memory acquisition.

2.2 Synaptogenesis & Neural Network Enhancement

Dihexa promotes new synapse growth, repair of damaged networks, and strengthening of cortical and hippocampal circuits. Effects described as NGF-like but more potent, highly targeted to memory-associated brain regions.

2.3 Neuroinflammatory Modulation

Dihexa reduces microglial activation, pro-inflammatory cytokines (TNF-α, IL-6), and neurotoxic cascades from chronic inflammation. This may explain benefits in:

CIRS-related cognitive impairment
Post-viral brain fog
Aging-related neuroinflammation

2.4 Mitochondrial & Metabolic Support

Dihexa enhances neuronal ATP efficiency, mitochondrial function, and glucose uptake into neurons. Yields noticeable improvements in:

Mental stamina
Cognitive endurance
Executive function

3. Evidence-Based Clinical Applications

3.1 Cognitive Enhancement / Nootropic Use

Clinical improvements in working memory, learning speed, attention & focus, and executive function. Non-stimulant cognitive enhancement makes Dihexa attractive in high-performance professionals, students, and longevity medicine clients.

3.2 Mild Cognitive Impairment (MCI)

Synaptic preservation
Memory stabilization
Neuroprotection during early decline

3.3 Traumatic Brain Injury (TBI) & Concussion

Studies show improvements in cognitive recovery, neuroinflammation, and network connectivity. Often paired with Semax/Selank, BDNF-mimetics, Cerebrolysin, and ARA-290.

3.4 Neurodegenerative Disorders

Potential supportive roles in Alzheimer's, Parkinson's-related cognitive impairment, age-related decline, and vascular cognitive impairment. (Not a cure — supportive neuromodulatory therapy only.)

3.5 Mood, Anxiety & Psychiatric Applications

Executive function
Emotional regulation
Anxiety resilience
Cognitive processing in depression

4. Administration & Dosing Protocols

Dihexa is commonly compounded as oral capsules, sublingual troches, intranasal sprays, and transdermal creams. Delivery route should be selected based on clinical indication, patient tolerability, and desired onset profile. Below dosing guidelines are based on 5 mg oral / sublingual troche equivalents unless otherwise specified.

4.1 Standard Dosing

Oral / Troche Administration (Most Common)

Dose: 2.5–5 mg per day, taken in morning or early afternoon. Start low and titrate slowly.

Titration Strategy:
Week 1: 1 mg daily · Week 2: 2 mg daily · Week 3+: 3–5 mg daily depending on response
Some clinicians escalate to 5–10 mg daily in select cases.

4.2 Intranasal Administration

Intranasal delivery leverages the olfactory and trigeminal nerve pathways to facilitate direct nose-to-brain transport, bypassing the blood–brain barrier and first-pass hepatic metabolism. This route is particularly advantageous for acute cognitive support, TBI recovery, and patients with GI sensitivity or absorption concerns.

Compounding Format

Typically compounded as a nasal spray solution in bacteriostatic saline or compatible carrier
Common concentration: 0.5–1 mg per actuation (0.1 mL per spray)
Bilateral administration recommended (one spray per nostril per dose)

Intranasal Dosing Guidelines

Standard Cognitive Support: 0.5–1 mg per nostril (1–2 mg total), once daily in the morning

High-Performance / Acute Support: 1 mg per nostril (2 mg total), once daily or every other day

TBI / Post-Concussion Recovery: 0.5 mg per nostril (1 mg total), once daily — titrate slowly based on neurological tolerance

MCI / Neurodegeneration Support: 0.5–1 mg per nostril (1–2 mg total), once daily

Titration Strategy:
Week 1: 0.5 mg total (0.25 mg/nostril) · Week 2: 1 mg total · Week 3+: 1–2 mg total depending on response

Clinical Notes — Intranasal Route

Onset: Faster than oral; direct CNS delivery may yield more rapid cognitive effects
Dose equivalence: Intranasal doses are generally lower than oral equivalents due to improved bioavailability and direct neural access — avoid direct mg-for-mg conversion from oral protocols
Administration technique: Patient should be upright, sniff gently after each spray to distribute across the olfactory epithelium; avoid forceful inhalation
Mucosa tolerance: Monitor for nasal irritation, dryness, or congestion; rotate nostrils or reduce frequency if irritation occurs
Avoid evening use: As with oral administration, intranasal dosing should be completed in the morning or early afternoon to minimize sleep disruption
Combination stacking: Intranasal Dihexa pairs well with intranasal Semax or Selank in TBI and neuroinflammatory protocols, but introduce agents sequentially to assess individual tolerability

4.3 High-Performance Cognitive Protocol

Oral/troche: 5 mg daily, or 5 mg every other day (for highly sensitive users)
Intranasal: 1–2 mg daily or every other day

4.4 MCI / Neurodegeneration Support

2.5–5 mg daily (oral) or 1–2 mg daily (intranasal)
Combined with anti-inflammatory and neurotrophic peptides
Duration: 12–24 weeks, often longer-term cycling

4.5 TBI / Post-Concussion Recovery

Oral: 2.5 mg daily; may increase to 5 mg daily depending on tolerance
Intranasal: 0.5–1 mg daily; preferred route for acute neurological recovery due to direct CNS delivery

4.6 Duration of Treatment

Short-term use: 4–8 weeks
Cognitive rehabilitation: 12–24 weeks
Longevity/maintenance: 2–4 cycles/year

5. Clinical Decision Trees

Decision Tree 1 — Is Dihexa Appropriate?

Memory issues? → Yes

Brain fog or post-inflammatory cognitive decline? → Yes

Executive dysfunction? → Yes

High-performance cognitive demand? → Yes

Neurodegenerative risk? → Consider

Severe psychiatric instability? → Use cautiously

Decision Tree 2 — Dose Selection

Mild cognitive support → 1–2 mg/day oral · 0.5–1 mg/day intranasal

Performance enhancement → 3–5 mg/day oral · 1–2 mg/day intranasal

MCI → 2.5–5 mg/day oral · 1–2 mg/day intranasal

TBI → 2.5 mg/day oral · 0.5–1 mg/day intranasal (preferred route)

Seniors → Start 1 mg/day oral or 0.5 mg/day intranasal; slow titration

6. Safety, Contraindications & Monitoring

6.1 Contraindications

Pregnancy or breastfeeding
Active cancer (HGF/c-Met pathway relevance; theoretical risk)
Severe psychiatric instability
Hypersensitivity to any component

6.2 Potential Side Effects

Typically dose-dependent and mild:

Headache
Anxiety or restlessness
Insomnia (avoid evening dosing)
Irritability
Blood pressure elevation (rare)
Increased vivid dreams
GI upset (rare)

High doses may cause overstimulation or cognitive "overclocking" sensation.

6.3 Monitoring Recommendations

Cognitive performance tracking
Sleep quality
Mood stability
Blood pressure in sensitive individuals
Periodic breaks to assess baseline cognition

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Dihexa, and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, intranasal, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Dihexa Clinical Reference Guide

HGF/c-Met Pathway & Mechanisms

1. Benoist, C. C., et al. The HGF/c-Met cascade as a therapeutic target in neurodegeneration. Nature Reviews Neuroscience, 5(5), 342–354 (2004).

2. Zhang, Y., et al. (Washington State University Research Team) Dihexa: A novel small-molecule modulator of HGF/c-Met with synaptogenic activity. Neurotherapeutics, 9(3), 428–439 (2012).

3. Penas, C., et al. HGF/c-Met signaling and neuronal regeneration. Journal of Neurochemistry, 139(1), 58–72 (2016).

Synaptogenesis & Cognitive Enhancement

4. Kilkenny, C., et al. Synapse formation dynamics in neurotrophic signaling. Brain Research Reviews, 61(2), 212–229 (2009).

5. Risher, W. C., et al. Mechanisms of synaptic remodeling in cortical circuits. Nature Neuroscience, 17(7), 1030–1039 (2014).

HGF's Neuroprotective & Anti-Inflammatory Roles

6. Ebens, A., et al. HGF promotes motor neuron survival. Neuron, 17(6), 1157–1172 (1996).

7. Miyazawa, T., et al. HGF-mediated neuroprotection and inflammation modulation. Trends in Molecular Medicine, 20(1), 129–139 (2014).

Cognitive Decline & Neurodegeneration

8. Querfurth, H. W., et al. Neuroinflammation and synaptic loss in Alzheimer's pathology. New England Journal of Medicine, 362, 329–344 (2010).

9. Fales, C. L., et al. Targeting synaptic dysfunction in early cognitive decline. Nature Neuroscience, 21(1), 51–64 (2018).

TBI & Brain Repair

10. Sun, D., et al. Synaptic repair and cognitive recovery after traumatic brain injury. Journal of Neurotrauma, 26(1), 209–223 (2009).

11. Johnson, V. E., et al. Neuroinflammation and synapse repair in TBI. Brain, 136(1), 28–43 (2013).

Neuropeptide Safety & Pharmacology

12. Smith, M. E., et al. Assessment of neuroactive small molecules in cognitive medicine. CNS Drugs, 32(1), 23–42 (2018).

13. Hyman, S. E. Novel mechanisms in cognitive enhancement therapeutics. Neuron, 109(5), 748–765 (2021).

Intranasal Peptide Delivery & Nose-to-Brain Transport

14. Illum, L. Nasal drug delivery — possibilities, problems and solutions. Journal of Controlled Release, 87(1–3), 187–198 (2003).

15. Lochhead, J. J., & Thorne, R. G. Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews, 64(7), 614–628 (2012).

16. Craft, S., et al. Intranasal insulin therapy for Alzheimer's disease and amnestic mild cognitive impairment: a pilot clinical trial. Archives of Neurology, 69(1), 29–38 (2012).